 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.169.259 |
| Chemical and physical data | |
| Formula | C21H28BrNO4 |
| Molar mass | 438.362 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Cimetropium bromide is a semisyntheticquaternary ammonium compound derived from reactingscopolamine (an alkaloid isolated frombelladonna) with cyclopropylmethyl bromide. It is used primarily as anantispasmodic agent for the treatment of gastrointestinal disorders such asirritable bowel syndrome (IBS).[1] Acting as a potentmuscarinic receptor antagonist, it inhibitsacetylcholine-mediated contractions in the smooth muscle of the digestive tract, thereby reducing spasms and alleviatingabdominal pain. Cimetropium bromide demonstrates efficacy in long-term management of IBS symptoms with a favorable tolerability profile and is generally administered orally. Its peripheral antimuscarinic effects are similar to those ofatropine but typically result in fewer or milder central nervous system side effects.[1]
Evidence does not support its use ininfantile colic.[2]
| Feature | Value |
|---|---|
| Number of Hydrogen Acceptors | 4 |
| The number of hydrogen donors | 1 |
| Number of Rotational Connections | 7 |
| Partition coefficient[3] (-{ALogP)}- | -2,1 |
| Solubility[4] (-{logS, log(mol/L}-)) | -3,6 |
| Polar surface[5] (-{PSA}-,Å2) | 102,1 |
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |